Likewise, current clinical research pays more attention to bi-specific and tri-specific antibodies development as well as combination therapy, e.g. using anti-PD-L1 together with anti-TIGIT antibodies for lung cancer patients (NCT04294810) in order to obtain, on the one hand, better efficacy, on the other hand, to solve treatment resistance problems (41, 42). This evidence concerns the gene CD274 and lung cancer.